Invokana Use In Pregnancy & Lactation

Pregnancy: There are no data from the use of canagliflozin in pregnant women. Studies in animals have shown reproductive toxicity (see Pharmacology: Toxicology: Preclinical Safety Data under Actions).
Canagliflozin should not be used during pregnancy. When pregnancy is detected, treatment with canagliflozin should be discontinued.
Breast-feeding: It is unknown whether canagliflozin and/or its metabolites are excreted in human milk. Available pharmacodynamic/toxicological data in animals have shown excretion of canagliflozin/metabolites in milk, as well as pharmacologically mediated effects in breast-feeding offspring and juvenile rats exposed to canagliflozin (see Pharmacology: Toxicology: Preclinical Safety Data under Actions). A risk to newborns/infants cannot be excluded. Canagliflozin should not be used during breast-feeding.
Fertility: The effect of canagliflozin on fertility in humans has not been studied. No effect on fertility were observed in animal studies (see Pharmacology: Toxicology: Preclinical safety data under Actions).